Search research articles
Contact Us
Filters
Showing results (21-30 of 49) with videos related to
Page
of 5
Sort By:
American Journal of Clinical Dermatology
|
February 26, 2017
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
Carle Paul, Craig Leonardi, Alan Menter, et al.
Dermatology and Therapy
|
May 29, 2021
Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
Jason E Hawkes, Kyoungah See, Russel Burge, et al.
The Journal of Investigative Dermatology
|
August 7, 2017
Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis"
Kristian Reich, Craig Leonardi, Kim Papp, et al.
American Journal of Clinical Dermatology
|
May 26, 2017
Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
Carle Paul, Craig Leonardi, Alan Menter, et al.
The New England Journal of Medicine
|
February 9, 2007
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G Krueger, Richard G Langley, Craig Leonardi, et al.
Dermatology and Therapy
|
August 1, 2024
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search
Lluís Puig, Hideki Fujita, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology
|
October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
Kim Papp, Craig Leonardi, Alan Menter, et al.
Journal of Drugs in Dermatology : JDD
|
August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
February 21, 2006
Relapse, rebound, and psoriasis adverse events: an advisory group report
Wayne Carey, Scott Glazer, Alice B Gottlieb, et al.
The Journal of Dermatological Treatment
|
October 21, 2016
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Kristian Reich, Craig Leonardi, Mark Lebwohl, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 49) with videos related to
Sort By:
Page
of 5
American Journal of Clinical Dermatology
|
February 26, 2017
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
Carle Paul, Craig Leonardi, Alan Menter, et al.
Dermatology and Therapy
|
May 29, 2021
Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
Jason E Hawkes, Kyoungah See, Russel Burge, et al.
The Journal of Investigative Dermatology
|
August 7, 2017
Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis"
Kristian Reich, Craig Leonardi, Kim Papp, et al.
American Journal of Clinical Dermatology
|
May 26, 2017
Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
Carle Paul, Craig Leonardi, Alan Menter, et al.
The New England Journal of Medicine
|
February 9, 2007
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G Krueger, Richard G Langley, Craig Leonardi, et al.
Dermatology and Therapy
|
August 1, 2024
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search
Lluís Puig, Hideki Fujita, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology
|
October 15, 2014
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
Kim Papp, Craig Leonardi, Alan Menter, et al.
Journal of Drugs in Dermatology : JDD
|
August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
February 21, 2006
Relapse, rebound, and psoriasis adverse events: an advisory group report
Wayne Carey, Scott Glazer, Alice B Gottlieb, et al.
The Journal of Dermatological Treatment
|
October 21, 2016
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Kristian Reich, Craig Leonardi, Mark Lebwohl, et al.
Page
of 5